Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
which leads to scarring and fibrosis of the lung tissue in a very short time via inflammatory processes. In order to identify potential therapeutic targets or progression biomarkers, blood serum ...
Fibromyalgia is a disorder that causes ... Sarcoidosis causes inflammation of the lungs, skin, and lymph nodes. It leads to granulomas, tiny, grain-like lumps. People with sarcoidosis might ...
RSBT-001 was evaluated in three separate, inducible experiments designed to test the ability of RSBT-001 to attenuate inflammation and fibrosis in human precision cut lung slices (PCLuS).